Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy

Brian D. Kavanagh, Bernard A. Fischer IV, Eileen M. Segreti, John B. Wheelock, Cecilia Boardman, Susan D. Roseff, Robert M. Cardinale, Stanley H Benedict, Adrian L. Goram

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Purpose: Red blood cell (RBC) transfusions or erythropoietin (EPO) can be used to evade the detrimental effects of anemia during radiotherapy, but the economic consequences of selecting either intervention are not well defined. The RBC transfusion needs during chemoradiotherapy for cervix cancer were quantified to allow comparison of RBC transfusion costs with the projected cost of EPO in this setting. Methods and Materials: For patients receiving pelvic radiotherapy, weekly cisplatin, and brachytherapy, the RBC units transfused during treatment were tallied. RBC transfusion costs per unit included the blood itself, laboratory fees, and expected value (risk multiplied by cost) of transfusion-related viral illness. EPO costs included the drug itself and supplemental RBC transfusions when hemoglobin was not adequately maintained. An EPO dosage based on reported usage in cervix cancer patients was applied. Results: Transfusions were given for hemoglobin <10 g/dL. Among 12 consecutive patients, 10 needed at least 1 U of RBC before or during treatment, most commonly after the fifth week. A total of 37 U was given during treatment, for an average of 3.1 U/patient. The sum total of the projected average transfusion-related costs was $990, compared with the total projected EPO-related costs of $3869. Conclusions: Because no proven clinical advantage has been documented for EPO compared with RBC transfusions to maintain hemoglobin during cervix cancer treatment, for most patients, transfusions are an appropriate and appealingly less expensive option.

Original languageEnglish (US)
Pages (from-to)435-441
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume51
Issue number2
DOIs
StatePublished - Oct 1 2001
Externally publishedYes

Keywords

  • Cervical cancer
  • Cost
  • Erythropoietin
  • Radiotherapy
  • Transfusion

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Fingerprint Dive into the research topics of 'Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy'. Together they form a unique fingerprint.

  • Cite this

    Kavanagh, B. D., Fischer IV, B. A., Segreti, E. M., Wheelock, J. B., Boardman, C., Roseff, S. D., Cardinale, R. M., Benedict, S. H., & Goram, A. L. (2001). Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 51(2), 435-441. https://doi.org/10.1016/S0360-3016(01)01645-5